A study showed that Lut/ZnO NPs could activate the PI3K/AKT signaling pathway, thereby inactivating FOXO1. Thus, Lut/ZnO NPs could alleviate NAFLD progression by reducing insulin resistance and antioxidant levels, as well as by regulating the insulin signaling pathway [41]. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.